Ozempic, Wegovy, Rybelsus (brand names) · Evidence-based safety and harm-reduction overview.
| Also known as | Ozempic, Wegovy, Rybelsus (brand names) |
| Category | GLP-1 (FDA-approved drug) |
| Class | GLP-1 receptor agonist |
| Route in humans | Subcutaneous injection once weekly or oral once daily |
| Half-life | Approximately 7 days |
| US legal status | FDA-approved as a prescription medication (Ozempic/Rybelsus for type 2 diabetes; Wegovy for weight management). Legal only with a valid prescription. Gray-market 'research' semaglutide is not the approved product and is not legal to sell for human use. |
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a 31-amino-acid peptide that mimics the natural gut hormone GLP-1. It slows gastric emptying, increases insulin secretion, and reduces appetite signaling in the brain. It is a well-studied, FDA-approved medicine available in injectable and oral formulations.
Semaglutide binds to GLP-1 receptors on pancreatic beta cells, stimulating glucose-dependent insulin secretion. It also acts on GLP-1 receptors in the hypothalamus and elsewhere to suppress appetite and increase satiety. Additionally, it slows gastric motility, extending the duration of nutrient absorption and promoting fullness. These coordinated effects lower blood glucose and reduce overall energy intake.
GLP-1 was discovered in the 1980s as a gut hormone regulating glucose-dependent insulin secretion. Semaglutide was developed by Novo Nordisk in the 2000s as a GLP-1 analog with improved stability and half-life compared to earlier compounds. It received FDA approval for type 2 diabetes (Ozempic) in 2017 and for chronic weight management (Wegovy) in 2021, following successful Phase III trials. Its dramatic efficacy has made it one of the most widely prescribed and discussed medications in recent years.
Large randomized controlled trials (STEP and SUSTAIN programs) involving thousands of participants demonstrate significant blood-sugar reduction in type 2 diabetes, clinically meaningful weight loss (average 5-15% of body weight depending on dose and population), and cardiovascular benefits in high-risk patients. Real-world data from millions of users confirm efficacy and an established safety profile.
In clinical trials and practice, semaglutide is administered once weekly via subcutaneous injection (Ozempic/Wegovy) or taken orally once daily (Rybelsus) at doses escalated from 0.25 mg to target doses of 1.0-2.4 mg depending on indication and tolerability. Dose adjustments are made over 4-12 weeks. Blood-glucose monitoring and periodic health assessment are standard.
This is general research/context information, not medical advice or a recommended protocol.
In clinical practice, semaglutide is often combined with metformin, SGLT2 inhibitors, or other diabetes medications for additive glucose-lowering effect. Combining with other weight-loss drugs (e.g., phentermine) is off-label and requires careful prescriber oversight. Do not combine with other GLP-1 agonists.
If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.
Compare testing optionsNot legally for human use. Approved semaglutide requires a prescription from a licensed healthcare provider; gray-market versions are unverified and risky.
No. Approved products are manufactured to pharmaceutical standards by FDA-regulated facilities and tested for identity, purity, strength, and stability. Research vials are not.
Both contain the same active ingredient but different formulations and indications. Ozempic is approved for type 2 diabetes; Wegovy for chronic weight management. Using one for the other's indication is off-label.
Most people regain weight when treatment stops unless lifestyle changes are sustained. It is a chronic management tool, not a cure.
Long-term safety data (5+ years) are still accumulating, but trial data through 2-3 years show a favorable benefit-risk profile in appropriate candidates under medical supervision.
Medical & legal disclaimer. This site is for informational and harm-reduction purposes only. It is not medical advice and is not a substitute for a licensed healthcare professional. The compounds discussed are largely not approved by the FDA for human use and many are sold strictly as research chemicals 'not for human consumption.' Nothing here is an endorsement to purchase, possess, or use any substance. Laws vary by jurisdiction. Always consult a qualified physician and follow the law where you live.
Some links on this page may be affiliate links. If you buy through them we may earn a commission at no extra cost to you. This never changes the safety information we publish.